Clinico-epidemiologic criteria and predictors of survival of rectal cancer among Egyptians in Delta region

Metwally, Islam H.; Abdelkhalek, Mohamed; Elbalka, Saleh S.; Zuhdy, Mohammad; Fareed, Ahmed M.; Eldamshity, Osama

doi:10.1016/j.jcol.2019.07.004

Cited by 9 publications

(3 citation statements)

References 21 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, there was a significant correlation between local recurrence and tumor size and neoadjuvant chemoradiation. Our 5 years incidence of local recurrence matched with the study of Metwally et al [7] that included 245 patients who registered at the Oncology Center, Mansoura University (OCMU) from 2006 to 2017, local recurrence incidence was 15.8%).…”

Section: Discussionsupporting

confidence: 71%

The Value of Tumor Size as a Prognostic Factor in Rectal Adenocarcinoma

Talayea

Ibrahim

Sedky

et al. 2022

JAMMR

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is the third frequent diagnosed cancer and third cause of cancer death. Curative intent surgery followed by chemoradiotherapy are the standard of care for patients with CRC to reduce local recurrence and enhance overall survival (OS). This study aimed to evaluate tumor size as a prognostic factor for rectal adenocarcinoma local recurrence. Patients and Methods: This retrospective phase II study reviewed 100 rectal adenocarcinoma patients who were treated and followed up for 5 years after treatment. The medical records were reviewed for all cases including demographic data, medical history, personal habits, uncontrolled chronic medical condition, presenting symptoms and signs, pathological data, laboratory investigations, diagnosis, radiological examination, treatment details and treatment outcome assessed by OS and disease-free survival (DFS). Results: During 5 years of follow up in our study, 12 patients (12%) had local recurrence. Patients with tumor size > 5 cm has a significantly shorter DFS. DFS within 2-yrs for tumours ≤5 cm 96%, while 5-years DFS was 90%. While for tumours >5cm, 2-years DFS was 70% and 55% for 5-years and more. In tumours size >5cm, 2-years OS was 75%, 3-years OS was 72% and 5-years was 70% While In tumours ≤ 5cm, overall survival was 84%. Patients who had neoadjuvant chemoradiation also had a significant low local recurrent rate with (p=.042) in multivariate analysis. Conclusions: Tumor size has a prognostic value in rectal adenocarcinoma. Tumor size >5 cm is associated with higher rate of local recurrence and worse DFS.

show abstract

Section: Discussionsupporting

confidence: 71%

The Value of Tumor Size as a Prognostic Factor in Rectal Adenocarcinoma

Talayea

Ibrahim

Sedky

et al. 2022

JAMMR

View full text Add to dashboard Cite

show abstract

“…Most of cases presented with locally advanced stage is due to lack of screening and delay in diagnosis because anorectal bleeding that represents 45% of symptoms of CRC is initially thought to be due to hemorrhoids (11) . Management of locally advanced rectal cancer is crucial to achieve better survival rate as survival of CRC is highly depended on stage at presentation, in Egypt the median overall survival is 2 years (stage I 44 months; stage IV 8 months) (12) . The role of multimodality treatment in LARC is to decrease recurrence rate and improve survival (13) .…”

Section: Discussionmentioning

confidence: 99%

Total Neoadjuvant Therapy Using Short Course Radiotherapy Followed by Chemotherapy in Locally Advanced Rectal Cancer

Elzayata¹,

Akla²,

Taemaa³

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: The most common neoadjuvant therapy for locally advanced rectal cancer is fluoropyrimidine-based chemotherapy combined with radiation (45-50.4 Gy) (LARC). Recently many studies focusing on shifting systemic chemotherapy to preoperative setting to increase pathological complete response rate (pCR).Patients & Methods: This is a randomized controlled trial (RCT) of stage II-III rectal cancer patients treated from October 2020 to April 2022. They were randomized into: Experimental group: Total neoadjuvant therapy (TNT) with short course radiotherapy (25 Gy) then chemotherapy (Capecitabine and Oxaliplatin) for 6 cycles followed by total mesorectal excision (TME). Control group: Standard long course concurrent chemo radiotherapy (LC-CCRT, 45-50.4Gy) with Capecitabine followed by TME and adjuvant chemotherapy. Primary end points were pathological complete response (pCR) and disease related treatment failure (DrTF). Secondary end points were restricted mean survival time at 12 months (RMST), toxicity and surgical complications. Results: High risk criteria as N2 and infiltrated mesorectal fascia (MRF) were statistically higher in TNT group (p=0.005, p= 0.04 respectively). Complete response was achieved radiologically in 11.5% and pathologically in 33.3 % exclusively in TNT group. Restricted mean survival time (RMST) at 12 months was 11.6 months in TNT group and 11.1 months in control group. Pathological complete response was statistically correlated to improvement in DrTF and RMST at 12 months (p =0.01). Conclusion: Short course radiotherapy with neoadjuvant chemotherapy is a good alternative to the standard LC-CCRT with less hospital treatment days and cost especially after COVID 19 pandemic.

show abstract

“…2 CRC survival rates are highly dependent upon the disease stage at diagnosis: at the localized stage, it is 90%; 70% at regional disease, and 10% for patients diagnosed with distant metastasis. 3 Inflammatory bowel disease (IBD), considered a risk factor for CRC, represents 1-2% of all CRC cases. Longitudinal investigations have shown that the severity of colonic inflammation, the length of bowel involvement, and the presence of primary sclerosing cholangitis are all indicators of the development of CRC.…”

Section: Introductionmentioning

confidence: 99%

Assessment of long noncoding RNA CCAT1 using real time-polymerase chain reaction in colorectal cancer patients

Refae

2024

EJI

View full text Add to dashboard Cite

Colorectal cancer (CRC) is linked to high mortality, mainly when discovered in its advanced stages. Several studies have pointed to the role of epigenetic factors in CRC and other cancers. Long non-coding RNAs (lncRNAs) are involved in the initiation, progression, metastasis, and modulation of the response to chemotherapeutic modalities of CRC as vital contributors to epigenetic mechanisms. Colon cancer-associated transcript-1 (CCAT1) is one of the lncRNAs that have been dysregulated in serum samples, providing a non-invasive route for diagnosing CRC patients. This study aimed to determine the role of CCAT1 expression as diagnostic and prognostic markers. We tested the associations of CCAT1 expression with serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9). The study included three groups: 41 patients with colorectal cancer, 39 patients with precancerous benign colorectal diseases, and 20 normal control individuals. CEA and CA 19-9 were measured by an immunoassay automated system. The expression level of CCAT1 was assessed by a real-time polymerase chain reaction. There was a statistically significant elevation of serum CEA levels in patients with CRC compared to patients with precancerous benign colorectal diseases. Furthermore, there was no statistically significant difference in serum CA 19-9 levels between all groups (p = 0.102). Interestingly, CCAT1 expression was significantly upregulated in the blood of CRC patients compared to the precancerous benign colorectal diseases group (p = 0.009) and the control group (p<0.001). Also, expression of CCAT1 was significantly elevated in patients with precancerous benign colorectal diseases compared to the control group (p=0.004). In conclusion, measuring the expression level of CCAT1 is more advised than assessment of CEA and CA 19-9 for the early diagnosis and prognosis of colorectal cancer.

show abstract

Clinico-epidemiologic criteria and predictors of survival of rectal cancer among Egyptians in Delta region

Cited by 9 publications

References 21 publications

The Value of Tumor Size as a Prognostic Factor in Rectal Adenocarcinoma

The Value of Tumor Size as a Prognostic Factor in Rectal Adenocarcinoma

Total Neoadjuvant Therapy Using Short Course Radiotherapy Followed by Chemotherapy in Locally Advanced Rectal Cancer

Assessment of long noncoding RNA CCAT1 using real time-polymerase chain reaction in colorectal cancer patients

Contact Info

Product

Resources

About